The multilayered postconfluent cell culture as a model for drug screening.

[1]  G. Peters,et al.  Thymidylate Synthase Expression in Patients with Colorectal Carcinoma Using a Polyclonal Thymidylate Synthase Antibody in Comparison to the TS 106 Monoclonal Antibody , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[3]  C. L. van der Wilt,et al.  Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. , 2000, European journal of cancer.

[4]  G. J. Peters,et al.  Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. , 1999, Cancer research.

[5]  G. Peters,et al.  Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines , 1999, British Journal of Cancer.

[6]  G. Peters,et al.  Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. , 1999, Anti-cancer drugs.

[7]  G. Peters,et al.  Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. , 1999, European journal of cancer.

[8]  P. Loadman,et al.  Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. , 1998, British Journal of Cancer.

[9]  G. Peters,et al.  Postconfluent multilayered cell line cultures for selective screening of gemcitabine. , 1998, European journal of cancer.

[10]  R. Ozols.  Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Peters,et al.  Combination chemotherapy studies with gemcitabine. , 1997, Seminars in oncology.

[12]  E. Rowinsky,et al.  The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. , 1996, Critical reviews in oncology/hematology.

[13]  G. Peters,et al.  Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. , 1996, General pharmacology.

[14]  G. Peters,et al.  Synergistic interaction between cisplatin and gemcitabine in vitro. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Neijt,et al.  Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients , 1995, Anti-cancer drugs.

[16]  G. Peters,et al.  Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. , 1995, European journal of cancer.

[17]  G. Peters,et al.  DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? , 1995, British Journal of Cancer.

[18]  G. Peters,et al.  Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. , 1995, Molecular pharmacology.

[19]  G. Peters,et al.  Three dimensional cell cultures as a model system to evaluate the biological activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine) , 1995 .

[20]  G. Giaccone.  New drugs in non-small cell lung cancer. An overview. , 1995, Lung cancer.

[21]  S. Meijer,et al.  Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Peters,et al.  Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. , 1994, Biochemical pharmacology.

[23]  N. Gibson,et al.  Increased activity and expression of NAD(P)H:quinone acceptor oxidoreductase in confluent cell cultures and within multicellular spheroids. , 1994, Cancer research.

[24]  O. Fodstad,et al.  Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  L. Johnson.  Posttranscriptional regulation of thymidylate synthase gene expression , 1994, Journal of cellular biochemistry.

[26]  J. Stables,et al.  Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression. , 1994, Biochemical pharmacology.

[27]  B. Sikic.  Modulation of multidrug resistance: at the threshold. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Keyomarsi,et al.  The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. , 1993, The Journal of biological chemistry.

[29]  H. Pinedo,et al.  The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. , 1993, British Journal of Cancer.

[30]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[31]  R. Ferone,et al.  Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. , 1993, Cancer research.

[32]  O. Fodstad,et al.  Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. , 1992, Cancer research.

[33]  G. Peters,et al.  Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. , 1992, British Journal of Cancer.

[34]  G. Peters,et al.  In vitro chemosensitivity testing of multilayered microcultures. , 1992, Anticancer research.

[35]  B. Chauffert,et al.  Confluence‐dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells , 1992, International journal of cancer.

[36]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[37]  P. Workman,et al.  The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. , 1991, Cancer communications.

[38]  G. Peters,et al.  Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. , 1991, European journal of cancer.

[39]  J. Schornagel,et al.  Membrane transport of methotrexate in a squamous carcinoma cell line adapted to low folate concentrations. , 1991, Anticancer research.

[40]  B. Chauffert,et al.  Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion. , 1990, Cancer research.

[41]  A. Barbat,et al.  Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. , 1990, Cancer research.

[42]  J. Bancroft,et al.  Theory and Practice of Histological Techniques , 1990 .

[43]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[44]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[45]  Tritton Tr,et al.  How to kill cancer cells: membranes and cell signaling as targets in cancer chemotherapy. , 1990 .

[46]  L. Penn,et al.  C-MYC: evidence for multiple regulatory functions. , 1990, Seminars in cancer biology.

[47]  L. Liu,et al.  Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. , 1988, Cancer research.

[48]  R. Sutherland.  Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[49]  Y. Lu,et al.  Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. , 1988, The Journal of biological chemistry.

[50]  A. Barbat,et al.  Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. , 1988, Cancer research.

[51]  W. Earnshaw,et al.  Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[52]  W. Bodmer,et al.  Monoclonal antibodies to human colorectal epithelium: Markers for differentiation and tumour characterization , 1987, International journal of cancer.

[53]  S. Carter,et al.  Fundamentals of Cancer Chemotherapy , 1986 .

[54]  R. Sutherland.  Importance of critical metabolites and cellular interactions in the biology of microregions of tumors , 1986, Cancer.

[55]  H. Gabbert,et al.  Oxygenation and differentiation in multicellular spheroids of human colon carcinoma. , 1986, Cancer research.

[56]  L. Smets,et al.  S1-phase cells of the leukemic cell cycle sensitive to 1-beta-D-arabinofuranosylcytosine at a high-dose level. , 1985, Cancer research.

[57]  R. Langer,et al.  A new method for the three-dimensional in vitro growth of human cancer cells. , 1983, Experimental cell research.

[58]  A. Pardee,et al.  Growth of Cells in Hormonally Defined Media , 1982 .

[59]  B Drewinko,et al.  Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. , 1981, Cancer research.

[60]  J. Byfield,et al.  Surgical adjuvant therapy in colon carcinoma: A human tumor spheroid model for evaluating radiation sensitizing agents , 1981, Cancer.

[61]  S. Hamamoto,et al.  Sustained growth and three-dimensional organization of primary mammary tumor epithelial cells embedded in collagen gels. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Yuhas,et al.  Multicellular tumor spheroid formation by breast cancer cells isolated from different sites. , 1978, Cancer research.

[63]  A. Goldin,et al.  Chemotherapy of human colon cancer xenografts in athymic nude mice , 1977, Cancer.

[64]  Twentyman Pr.  Comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro model systems. , 1976 .

[65]  Inch Wr,et al.  Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture. , 1970 .

[66]  A. Seligman,et al.  ENZYME ALTERABLE ALKYLATING AGENTS. V. DESIGN OF SULFUR MUSTARDS WITH VARYING DEGREES OF HYDROLYTIC STABILITY IN A SEARCH FOR SHORT BIOLOGICAL HALF-LIFE AGENTS. , 1963, Journal of the National Cancer Institute.

[67]  J. Leighton.  A sponge matrix method for tissue culture; formation of organized aggregates of cells in vitro. , 1951, Journal of the National Cancer Institute.

[68]  G. Scagliotti,et al.  Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Clayton,et al.  Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. , 1997, British Journal of Cancer.

[70]  G. Peters,et al.  Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. , 1993, European journal of cancer.

[71]  H. Hansen,et al.  Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). , 1993, Cancer treatment reviews.

[72]  G. Peters,et al.  Evaluation of immunohistochemical staining and activity of thymidylate synthase in cell lines. , 1993, Advances in experimental medicine and biology.

[73]  Kenneth D. Paull,et al.  Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen , 1992 .

[74]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Laurence H. Baker,et al.  Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development , 1992, Developments in Oncology.

[76]  G. Snow,et al.  Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. , 1991, Cancer research.

[77]  T. Chou,et al.  Synergism and antagonism in chemotherapy , 1991 .

[78]  R. Hoffman.  In vitro sensitivity assays in cancer: A review, analysis, and prognosis , 1991, Journal of clinical laboratory analysis.

[79]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .

[80]  G. Adams,et al.  Selective Activation of Drugs by Redox Processes , 1990, NATO ASI Series.

[81]  P. Workman.  Special article: The Cell membrane and cell signals: New targets for novel anticancer drugs , 1990 .

[82]  G. Adams,et al.  The Assessment of Bioreductive Drug Toxicity in vitro and in Experimental Tumours in vivo , 1990 .

[83]  B. Rotman,et al.  Cellular viability in human tumor micro-organ cultures: in situ quantitation by image processing. , 1989, Selective cancer therapeutics.

[84]  A. Bodley,et al.  Regulation of DNA topoisomerases during cellular differentiation. , 1987, NCI monographs : a publication of the National Cancer Institute.

[85]  C. Denis,et al.  Effect of glutamine deprivation and glutamate or ammonium chloride addition on growth rate, metabolism and differentiation of human colon cancer cell-line HT29. , 1986, The International journal of biochemistry.

[86]  F. Miller,et al.  Assessing tumor drug sensitivity by a new in vitro assay which preserves tumor heterogeneity and subpopulation interactions , 1984, Journal of cellular physiology. Supplement.